<DOC>
	<DOC>NCT01203371</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.</brief_summary>
	<brief_title>Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS</brief_title>
	<detailed_description>Inclusion Criteria: Men ≥ 50 years Signs and symptoms of BPH A total IPSS of ≥ 10 Prostate volume of ≥20 mL (estimated by ultrasonography) PVR &gt; 150mL</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Naftopidil</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Men ≥ 50 years Signs and symptoms of BPH IPSS of ≥ 10 Prostate volume of ≥ 20 mL PVR &gt; 150 mL History of allergy to a AR antagonists Treatment with antiandrogen drugs Drugs with anticholinergic activity Significant history of orthostatic hypotension Concomitant neurological diseases Known or suspected neurogenic bladder dysfunction Carcinoma of the prostate or bladder Previous surgery for BPH or bladder neck obstruction History of recurrent UTI Concomitant active UTI</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>naftopidil</keyword>
	<keyword>symptoms of lower urinary tract</keyword>
	<keyword>benign prostate hyperplasia</keyword>
	<keyword>LUTS</keyword>
</DOC>